1. Scrip
  2. >>R&D
  3. >>Pipeline Watch

Pipeline Watch: 12 Approvals And 17 Phase III Readouts

The Week In R&D

 
• By Scrip Team

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Image
• Source: Alamy

The table above records the past week’s major catalyst events that occurred in the late-stage pipeline during the past week (see table for relevant dates), created using Citeline’s Biomedtracker.

The table lists drugs at Phase II or above for which an important catalyst was recorded during the week, according...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pipeline Watch

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: Ten Approvals And Four Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: One Approval And 23 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: Two Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Clinical Trials

Zai Lab Takes Lead In DLL3 Lung Cancer ADC Race

 
• By Andrew McConaghie

Having built its reputation as the ‘Gateway to China’ for global firms, Zai is going global itself, moving its potential first-in-class ADC into Phase III development.

Junshi Eyes Approval For Subcutaneous Anti PD-1 With Milestone Phase III Win

 
• By Manas Mishra

Clinical Data Readout: Armed with positive data from the first Phase III trial of a China-made subcutaneous anti-PD-1 antibody, Junshi is chasing other heavyweights such as Keytruda and Opdivo, as well as a domestic rival.

J&J’s Anti-Tau Asset Posdinemab Fails In Phase II Alzheimer’s Study

 
• By Mandy Jackson

Johnson & Johnson said its microtubule binding region (MTBR)-targeting candidate posdinemab did not slow cognitive decline in early Alzheimer’s disease in the Phase II Autonomy trial, marking another setback as anti-tau agents continue to deliver mixed results.